OBJECTIVE: This retrospective study was conducted to determine the usage patterns and tolerability of tirofiban and eptifibatide during the first year of their use. METHODS: We have assessed the appropriate use of these drugs according to the criteria implemented by the Clinical Institute of Cardiovascular Disease as part of a protocol for treating acute coronary syndrome with non-ST segment elevation. RESULTS: 37 patients received tirofiban and 19 patients received eptifibatide. These patients were at high risk of poor outcomes such as myocardial infarction or death. Tirofiban and eptifibatide were used according to the indication criteria: only one case fell outside them. Dosing, time for drug initiation (from last chest pain) and time of infusion were considered appropriate. Tirofiban was involved in two cases of minor bleeding complications and eptifibatide in one case of thrombocytopenia (80,000 platelets per millimeter). These mild adverse drug reactions were reversible with the early withdrawal of the drugs. CONCLUSIONS: This study shows that tirofiban and eptifibatide have been used optimally, with a close adherence to the pre-established protocol. Both drugs have shown a good level of tolerability.
OBJECTIVE: This retrospective study was conducted to determine the usage patterns and tolerability of tirofiban and eptifibatide during the first year of their use. METHODS: We have assessed the appropriate use of these drugs according to the criteria implemented by the Clinical Institute of Cardiovascular Disease as part of a protocol for treating acute coronary syndrome with non-ST segment elevation. RESULTS: 37 patients received tirofiban and 19 patients received eptifibatide. These patients were at high risk of poor outcomes such as myocardial infarction or death. Tirofiban and eptifibatide were used according to the indication criteria: only one case fell outside them. Dosing, time for drug initiation (from last chest pain) and time of infusion were considered appropriate. Tirofiban was involved in two cases of minor bleeding complications and eptifibatide in one case of thrombocytopenia (80,000 platelets per millimeter). These mild adverse drug reactions were reversible with the early withdrawal of the drugs. CONCLUSIONS: This study shows that tirofiban and eptifibatide have been used optimally, with a close adherence to the pre-established protocol. Both drugs have shown a good level of tolerability.
Authors: E Boersma; K S Pieper; E W Steyerberg; R G Wilcox; W C Chang; K L Lee; K M Akkerhuis; R A Harrington; J W Deckers; P W Armstrong; A M Lincoff; R M Califf; E J Topol; M L Simoons Journal: Circulation Date: 2000-06-06 Impact factor: 29.690
Authors: E M Antman; C H McCabe; E P Gurfinkel; A G Turpie; P J Bernink; D Salein; A Bayes De Luna; K Fox; J M Lablanche; D Radley; J Premmereur; E Braunwald Journal: Circulation Date: 1999-10-12 Impact factor: 29.690
Authors: E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald Journal: N Engl J Med Date: 1996-10-31 Impact factor: 91.245
Authors: Evangelos K Oikonomou; Theodoros I Repanas; Christos Papanastasiou; Damianos G Kokkinidis; Michael Miligkos; Attila Feher; Dipti Gupta; Polydoros N Kampaktsis Journal: Thromb Res Date: 2016-09-24 Impact factor: 3.944